AstraZeneca receives positive CHMP opinion for subcutaneous Saphnelo in EU
PositiveFinancial Markets

AstraZeneca has received a positive opinion from the CHMP regarding its subcutaneous formulation of Saphnelo in the EU. This is significant as it could enhance patient access to this important treatment, potentially improving outcomes for those with autoimmune diseases. The approval reflects AstraZeneca's commitment to innovation in healthcare and could lead to a broader adoption of Saphnelo across Europe.
— Curated by the World Pulse Now AI Editorial System